MedPath

MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Extension Study of MT-1303

Phase 2
Completed
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Drug: MT-1303-High
Drug: MT-1303-Low
Drug: MT-1303-Middle
First Posted Date
2013-07-02
Last Posted Date
2016-04-11
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
367
Registration Number
NCT01890655
Locations
🇬🇧

Research Site, City name, United Kingdom

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

Phase 1
Completed
Conditions
Diabetic Nephropathy
Interventions
Drug: MT-3995-Low
Drug: Placebo
Drug: MT-3995-High
First Posted Date
2013-06-28
Last Posted Date
2015-01-27
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
51
Registration Number
NCT01889277
Locations
🇯🇵

Koukan Hospital, Kawasaki, Kanagawa Pref., Japan

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

Phase 1
Completed
Conditions
Dyslipidemia
Interventions
Drug: Placebo
Drug: TA-8995
First Posted Date
2013-06-17
Last Posted Date
2013-06-17
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
61
Registration Number
NCT01879020
Locations
🇩🇪

Momentum Pharma Services GmbH, Hamburg, Germany

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

Phase 1
Completed
Conditions
Dyslipidemia
Interventions
Drug: TA-8995
Drug: Placebo
First Posted Date
2013-06-17
Last Posted Date
2013-06-17
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
96
Registration Number
NCT01878474
Locations
🇬🇧

Hammersmith Medicines Research (HMR), London, United Kingdom

The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Phase 3
Completed
Conditions
Perennial Allergic Rhinitis
Interventions
First Posted Date
2013-05-23
Last Posted Date
2015-12-15
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
473
Registration Number
NCT01861522
Locations
🇯🇵

Reserch site, Toyama, Japan

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

Phase 3
Completed
Conditions
Atopic
Dermatitis
Interventions
First Posted Date
2013-04-26
Last Posted Date
2018-05-25
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
303
Registration Number
NCT01840605
Locations
🇯🇵

Medical Corporation Kojinkai Asanuma Dermatology Clinic, Hokkaido, Japan

Safety and Tolerability Study of MCI-196

Phase 3
Terminated
Conditions
Hyperphosphatemia
Chronic Kidney Disease
Not on Dialysis
Paediatric
Interventions
First Posted Date
2013-03-26
Last Posted Date
2015-05-27
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
4
Registration Number
NCT01818687
Locations
🇬🇧

Investigational site, London, United Kingdom

Long-term Extension Study of MCI-196

Phase 3
Terminated
Conditions
Paediatric
Dialysis
Hyperphosphatemia
Chronic Kidney Disease
Interventions
First Posted Date
2013-03-20
Last Posted Date
2015-05-27
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
6
Registration Number
NCT01814917
Locations
🇬🇧

Investigational site, London, United Kingdom

Dose-finding Study of MCI-196

Phase 3
Terminated
Conditions
Hyperphosphatemia
Paediatric
Chronic Kidney Disease
Dialysis
Interventions
Drug: CBPB
Drug: colestilan-L
Drug: colestilan-H
Drug: colestilan-M
First Posted Date
2013-03-20
Last Posted Date
2015-05-27
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
10
Registration Number
NCT01814904
Locations
🇬🇧

Investigational site, London, United Kingdom

Clinical Pharmacology Study of MP-424

Phase 1
Completed
Conditions
Chronic Hepatitis C
Interventions
Drug: MP-424
First Posted Date
2013-01-11
Last Posted Date
2017-01-26
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
26
Registration Number
NCT01766167
© Copyright 2025. All Rights Reserved by MedPath